Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1993 2
1994 5
1995 2
1996 7
1997 2
2000 1
2002 1
2003 1
2005 2
2006 2
2007 5
2008 4
2009 6
2010 2
2011 9
2012 10
2013 8
2014 8
2015 6
2016 1
2018 1
2019 2
2021 1
2022 1
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

80 results
Results by year
Filters applied: . Clear all
Page 1
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.
Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U; VIEW 1 and VIEW 2 Study Groups. Heier JS, et al. Among authors: sandbrink r. Ophthalmology. 2012 Dec;119(12):2537-48. doi: 10.1016/j.ophtha.2012.09.006. Epub 2012 Oct 17. Ophthalmology. 2012. PMID: 23084240 Clinical Trial.
Fysiek consult, telefonisch consult of videoconsult?
Sandbrink R, Carsouw E, de Jong L, Weel A. Sandbrink R, et al. Tijdschr Bedr Verzekeringsgeneeskd. 2021;29(6-7):6-9. doi: 10.1007/s12498-021-1395-1. Epub 2021 Jun 18. Tijdschr Bedr Verzekeringsgeneeskd. 2021. PMID: 34127882 Free PMC article. Dutch. No abstract available.
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA; CARE-MS II investigators. Coles AJ, et al. Among authors: sandbrink r. Lancet. 2012 Nov 24;380(9856):1829-39. doi: 10.1016/S0140-6736(12)61768-1. Epub 2012 Nov 1. Lancet. 2012. PMID: 23122650 Clinical Trial.
Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies.
Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, Brown DM, Chong V, Nguyen QD, Ho AC, Ogura Y, Simader C, Jaffe GJ, Slakter JS, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Sowade O, Zeitz O, Norenberg C, Sandbrink R, Heier JS. Schmidt-Erfurth U, et al. Among authors: sandbrink r. Ophthalmology. 2014 Jan;121(1):193-201. doi: 10.1016/j.ophtha.2013.08.011. Epub 2013 Sep 29. Ophthalmology. 2014. PMID: 24084500 Clinical Trial.
Reply: To PMID 25068637.
Ogura Y, Roider J, Korobelnik JF, Holz FG, Simader C, Schmidt-Erfurth U, Vitti R, Berliner AJ, Hiemeyer F, Stemper B, Zeitz O, Sandbrink R; GALILEO Study Group. Ogura Y, et al. Among authors: sandbrink r. Am J Ophthalmol. 2015 Mar;159(3):608. doi: 10.1016/j.ajo.2014.12.016. Am J Ophthalmol. 2015. PMID: 25681024 No abstract available.
Expression of L-APP mRNA in brain cells.
Sandbrink R, Banati R, Masters CL, Beyreuther K, König G. Sandbrink R, et al. Ann N Y Acad Sci. 1993 Sep 24;695:183-9. doi: 10.1111/j.1749-6632.1993.tb23049.x. Ann N Y Acad Sci. 1993. PMID: 8239280 Review.
Elements of informed consent for pharmacogenetic research; perspective of the pharmacogenetics working group.
Anderson DC, Gomez-Mancilla B, Spear BB, Barnes DM, Cheeseman K, Shaw PM, Friedman J, McCarthy A, Brazell C, Ray SC, McHale D, Hashimoto L, Sandbrink R, Watson ML, Salerno RA, Cohen N, Lister CE; Pharmacogenetics Working Group. Anderson DC, et al. Among authors: sandbrink r. Pharmacogenomics J. 2002;2(5):284-92. doi: 10.1038/sj.tpj.6500131. Pharmacogenomics J. 2002. PMID: 12439734 Review. No abstract available.
Body mass index as a predictor of MS activity and progression among participants in BENEFIT.
Manuel Escobar J, Cortese M, Edan G, Freedman MS, Hartung HP, Montalbán X, Sandbrink R, Radü EW, Barkhof F, Wicklein EM, Kappos L, Ascherio A, Munger KL. Manuel Escobar J, et al. Among authors: sandbrink r. Mult Scler. 2022 Jul;28(8):1277-1285. doi: 10.1177/13524585211061861. Epub 2022 Jan 7. Mult Scler. 2022. PMID: 34994579 Free PMC article.
80 results